HOME >> BIOLOGY >> NEWS
Eczema patients lack natural antibiotic in skin

Researchers at National Jewish Medical and Research Center report in the October 10 issue of the New England Journal of Medicine that patients with atopic dermatitis, also known as eczema, are susceptible to bacterial infections of their skin because they fail to produce effective amounts of two antimicrobial peptides. The findings demonstrate for the first time the clinical significance of these peptides in humans, and suggest that a medication containing or inducing the peptides may one day be used to fight the infections that plague millions of atopic dermatitis patients. The accompanying editorial in the journal called it a "seminal study."

"This study helps explain why 90 percent of atopic dermatitis patients are colonized by staphylococcus aureus and 30 percent develop active infections," said the study's senior author, Donald Leung, M.D., Ph.D., Head of Pediatric Allergy-Immunology at National Jewish Medical and Research Center, in Denver. "It is important to understand why people with this common skin disease are so susceptible to skin infections, especially in light of recent widespread concerns that they can develop severe infections after receiving a smallpox vaccination. Interestingly, these antimicrobial peptides are also needed to combat viral infections and therefore could account for the susceptibility of atopic dermatitis patients to eczema vaccinatum and herpes simplex infections."

Atopic dermatitis is a common, chronic skin disease characterized by dry, itchy and easily irritated skin. It occurs most commonly in infants and young children, but can persist into adulthood. Severe cases can lead to sleep deprivation, chronic bacterial infections, and depression. Approximately one in nine people in the United States suffer from this disease at some point. Along with other allergic diseases, its prevalence has grown significantly in recent years.

Immunologists recently identified peptides in the skin that help fight incipient in
'"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
9-Oct-2002


Page: 1 2 3

Related biology news :

1. Trial shows which brain cancer patients benefit from temozolomide
2. Study of flu patients reveals virus outsmarting key drug
3. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay
4. Activated signaling pathway may predict lung cancer patients response to gefitinib
5. Targeted therapy for lung cancer patients shows promise in extending lives
6. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
7. Study finds that only half of a commonly used cancer drug is activated in cancer patients
8. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
9. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
10. Lung cancer patients in Japan, United States react differently to the same chemotherapy regimen
11. Gene expression ratio identifies risk of recurrence in breast cancer patients receiving tamoxifen

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... Properties (NYSE: CUZ ) announced today that Amgen, ... 10-year, approximately 125,000 square-foot lease at Corporate Center, a 1,224,000 ... submarket of Tampa, FL. ... for their new location in Tampa ," ... of Cousins Properties. "Amgen is a cutting-edge global company at ...
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 /PRNewswire/ ... company developing novel therapies for neurodegenerative diseases, including ... confirmation that its application to list the Company,s ... been approved by The NASDAQ Stock Market, a ... of the listing, Neurotrope will ring the Opening Bell ...
(Date:3/24/2017)... 24, 2017 On Thursday, March ... at 5,817.69, down 0.07%; the Dow Jones Industrial Average ... S&P 500 closed at 2,345.96, marginally dropping 0.11%. US ... in green, 4 sectors finished in red, and 1 ... has initiated reports coverage on the following Biotechnology equities: ...
Breaking Biology Technology:
Cached News: